PeproMene Bio, Inc.
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL (NCT05370430) | PeproMene Bio, Inc. | 2022-06-13 |
| BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL (NCT04690595) | PeproMene Bio, Inc. | 2021-05-18 |
Track PeproMene Bio, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.